Published in Cell reports medicine, Results Of a vhio-also study support, using Rad51 Testing to Complement Next-Generation Sequencing (NGS) For Precise PATENT SCATIFICATION and Treatment Selection In Metastatic Cancer (MPC).

Different genomic alterations in DNA Damage Repair (DDR) Pathways Occur in 20% to 25% of Advanced Prostate Cancer, Including Homologous recomberbination repair (hrr). Identifying the molecular characteristics and targetable mutations of Each Tumor has become an integral part of metastatic prostate cancer care.

“The Association of Homologous Recombination Repair Defects With Response to Treatment with Parp Inhibitors Marked The First Successful Application of Precision Medicine in PATHCERENTS” o, a medical oncologist at the vall d’ebron university hospital, co-leader of VHIO’s Prostate Cancer Group, and Co-Corresponding Author of this study.

“However, Several Challenges of NGS Testing Still IMPEDE The Widespread Implementation of Precision Medicine in Routine Metastatic Prostate Cancer Cancer Care,” Added Mateo.

“Refining Cancer Biomarker Strategies and Identifying New Tumor Markers that Complement Current NGS Methods Black Facilitate a More Precise PATINT SEARTIFICATION and Treatment Selection Process” Hio’s Experimental Therapeutics Group and Co-Corresponding Author of this present article.

Rad51 is a protein involved in homologous recombination repair (HRR) alterations. Developed in-House by Serra’s Laboratory, The Rad51 Assay is Based on the Detection of this Protein as a functional biomarker to potentially enhance the strateifications of Patients with Cancer DNA Damage Repair (DDR) Pathway.

Functional assays that can detect dynamic changes in HRR Capacity also also Support Patient Strategies Strategies and Help Prioritize NGS Testing WHEN Resources are Limited.

Comprehensive Analysis of DNA Damage

For this study, the Investigators Performed A Comprehensive Analysis of Homologous RePair Status Through Parallel Evaluation Using NGS and the Rad51 Test in 219 Primary or Metastatic Biopsies Anced prostate cancer.

Genomic analysis revised that the most frequently altred genes inclined TP53, Pten, Ar, MyC, BRCA2, ATM and BRCA1, Highlighting the Complex Genomic Landscape of MCRC.

Rad51 immunofluorescence showed that 21% of evaluable Samples Had a Rad51-Low Score, Indicating HRR Deficiency, and a High Sensitivity and Specificity for Identation for Identation Tumors with Brca1/2. Patients with Rad51-Low Scores Experienced Longer Progression Free Survival (PFS) on Treatment with Parp Inhibitors or Platinum Chemotherapy.

“Our results demonstrate the feasibility of using the rad51 biomarker to identify patients with homologous recombination Repair-Defective Prostate Cancer and Who May the there Itors, “said serra.

“This biomarker could complete complement ngs in clinical practice, particularly in cases with limited tissue availability where sequencing may not be posted,” Concluded Mateo.